Continuous Glucose Monitor Integration

The access route depends on the manufacturer, the market and the type of product you are building. Many diabetes platforms combine a direct vendor API for one brand with health platform data for others.

Before development starts, we list the CGM models your users actually wear, the countries you operate in and how quickly the data needs to arrive. That inventory usually determines which vendor conversations are needed and whether a health platform route is sufficient for a first release.

The core record is the estimated glucose value (EGV). Dexcom G6 and G7 typically produce a value every five minutes; FreeStyle Libre sensors may provide per-minute current readings and 15-minute history depending on model. Calibrations, events, alerts and device information add context where the source exposes them.

Derived metrics such as time in range (70 to 180 mg/dL per international consensus), glucose management indicator (GMI) and glycemic variability are useful, but they are calculations, not device outputs. We label them clearly, document the method and data sufficiency rules, and validate them against reference calculations.

Patients authorize sharing through the vendor's OAuth flow or by enabling health platform sync in the vendor app. Your consent model should explain who sees the data, how often it updates and whether it is monitored in real time.

On the business side, production API access, partner programs and commercial agreements are the norm rather than the exception for CGM data. We build these steps into the project timeline and confirm requirements with each vendor's current documentation. Security and privacy controls follow your HIPAA-aligned integration approach.

Data delays matter. If glucose data through an API or health platform is delayed, it should not be presented as live, and it should not drive urgent alerts. Interfaces must show the reading time clearly.

Software that displays CGM data alongside alarms, or that informs or drives dosing decisions, may be regulated as a medical device. iCGM designations, alternate controller enabled (ACE) pumps and automated insulin delivery systems are outside the scope of a simple data integration. We recommend obtaining regulatory advice early when your product approaches these areas.

CGM data supports diabetes care management, coaching programs, remote patient monitoring for people with type 1 or type 2 diabetes, gestational diabetes programs and clinical research. Retrospective review of glucose patterns is often the safest starting point.

Glucose data can be shared with clinical systems through EHR integration or FHIR Observations, with derived metrics clearly identified as calculated values.